ERBB2 and breast cancer: The effect of HER2-low status on the prognosis remains debatable among several studies. A number of series corroborate our findings [6,8,14,21] but others suggested worse outcomes for HER2-low in localized node-positive and luminal early BC, although these studies compared HER2-0/HER2 1+ versus HER2 2+/ISH negative patients [18,22].